DEVELOPMENTAL RESEARCH PROGRAM In an effort to promote innovative translational research in breast cancer, the Developmental Research Program is a major focus of this Breast SPORE. The support of pilot projects allows early, high-risk research to move fundamental research findings toward clinical application, as well as the migration of provocative clinical and population-based observations back to the laboratory in order to understand their mechanistic basis. We are providing faculty with both the research support and the protected effort to focus dedicated time to the development of projects in areas that will have the biggest impact for people at risk for or with breast cancer. Main criteria for selection and funding of developmental (pilot) projects include scientific merit, relevance to mammary biology and/or breast cancer, collaboration and potential for extramural peer-reviewed funding and publications. There is an emphasis on utilization of emerging technologies and approaches applicable to translational research in breast cancer, as well as on young investigators. During the current grant cycle, and with generous institutional matching to supplement the Breast SPORE budget, $667,149 were awarded to support 15 pilot projects. This investment has resulted in four R01 or R01-equivalent grants, totaling more than $2.5M (direct costs), $3.6M (total costs), and two foundation grant awards, totaling more than $370K (direct costs), $436K (total costs). There are 27 published manuscripts supported by this research and all awardees have presented their research at our SPORE monthly meeting or the VICC Breast Cancer Program and SPORE Monthly Series.

Public Health Relevance

DEVELOPMENTAL RESEARCH PROGRAM In an effort to promote innovative translational research in breast cancer, the Developmental Research Program is a major focus of this Breast SPORE. The support of pilot projects allows early, high-risk research to move fundamental research findings toward clinical application, as well as the migration of provocative clinical and population-based observations back to the laboratory in order to understand their mechanistic basis. We are providing faculty with both the research support and the protected effort to focus dedicated time to the development of projects in areas that will have the biggest impact for people at risk for or with breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA098131-18
Application #
9984319
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2003-08-07
Project End
2024-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
18
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
079917897
City
Nashville
State
TN
Country
United States
Zip Code
37232
Santos Guasch, Gabriela L; Beeler, J Scott; Marshall, Clayton B et al. (2018) p73 Is Required for Ovarian Follicle Development and Regulates a Gene Network Involved in Cell-to-Cell Adhesion. iScience 8:236-249
Croessmann, Sarah; Sheehan, Jonathan H; Lee, Kyung-Min et al. (2018) PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K? Inhibitors. Clin Cancer Res 24:1426-1435
Elion, David L; Cook, Rebecca S (2018) Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment. Oncotarget 9:29007-29017
Williams, Michelle M; Lee, Linus; Werfel, Thomas et al. (2018) Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis 9:21
Hyman, David M; Piha-Paul, Sarina A; Won, Helen et al. (2018) HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554:189-194
Luo, Na; Nixon, Mellissa J; Gonzalez-Ericsson, Paula I et al. (2018) DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat Commun 9:248
Sudhan, Dhivya R; Schwarz, Luis J; Guerrero-Zotano, Angel et al. (2018) Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial. Clin Cancer Res :
Werfel, Thomas A; Wang, Shan; Jackson, Meredith A et al. (2018) Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival. Cancer Res 78:1845-1858
Zhao, Shilin; Li, Chung-I; Guo, Yan et al. (2018) RnaSeqSampleSize: real data based sample size estimation for RNA sequencing. BMC Bioinformatics 19:191
Jovanovi?, Bojana; Sheng, Quanhu; Seitz, Robert S et al. (2017) Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue. BMC Cancer 17:241

Showing the most recent 10 out of 341 publications